Table 1.

Characteristics of adults with SCD in the VUMC and UNC cohorts (N = 300)

Patient characteristicsAll patients (N = 300)VUMC (n = 150)UNC (n = 150)P (cohorts)*HbSC/HbSβ+ (n = 75)HbSS/HbSβ0/HbSD (n = 225)P (phenotypes)*
Age at baseline, median (IQR), y 28.9 (22.5-40.6) 25.1 (18.7-31.6) 35.4 (26.0-43.8) <.001 31.1 (23.7-43.8) 28.6 (22.0-39.5) .150 
Follow-up, mean (SD), y 6.7 (3.3) 7.1 (3.7) 6.3 (2.9) .045 6.6 (3.4) 6.8 (3.3) .779 
Males, % 43.7 48.0 39.3 .130 48.0 42.2 .382 
SCD phenotype (HbSS/HbSβ0/HbSD), % 75.0 68.7 81.3 .011 NA NA NA 
Hemoglobin, mean (SD), g/dL 9.5 (1.8) 9.9 (1.8) 9.2 (1.8) .001 11.2 (1.6) 9.0 (1.5) <.001 
Reticulocyte, mean (SD), % (n = 265) 8.0 (5.6) 9.0 (6.5) 7.2 (4.6) .009 4.2 (3.0) 9.2 (5.7) <.001 
On hydroxyurea, % 58.7 60.0 57.3 .639 29.3 68.4 <.001 
Death, % 15.3 14.7 16.0 .749 16.0 15.1 .853 
Median age of survival for adults with SCD, by starting initial survival age (N = 300) 
 Median (95% CI): survival to ≥18 y 49.2 (44.4-58.4) (n = 300) 43.6 (40.6-59.5) (n = 150) 54.1 (46.3-62.9) (n = 150) .191 54.7 (38.6-62.9) 48.0 (44.4-58.4) .889 
 Median (95% CI): survival to ≥25 y 54.7 (46.3-60.6) (n = 198) 54.7 (43.3-60.6) (n = 80) 54.1 (46.3-62.9) (n = 118) .858 56.5 (38.6-62.9) (n = 53) 51.4 (44.9-59.5) (n = 145) .926 
 Median (95% CI): survival to ≥30 y 56.5 (46.3-60.6) (n = 138) 54.7 (40.6-undefined) (n = 42) 56.5 (46.4-62.9) (n = 96) .815 54.7 (38.6-62.9) (n = 38) 54.1 (46.1-66.1) (n = 100) .760 
Patient characteristicsAll patients (N = 300)VUMC (n = 150)UNC (n = 150)P (cohorts)*HbSC/HbSβ+ (n = 75)HbSS/HbSβ0/HbSD (n = 225)P (phenotypes)*
Age at baseline, median (IQR), y 28.9 (22.5-40.6) 25.1 (18.7-31.6) 35.4 (26.0-43.8) <.001 31.1 (23.7-43.8) 28.6 (22.0-39.5) .150 
Follow-up, mean (SD), y 6.7 (3.3) 7.1 (3.7) 6.3 (2.9) .045 6.6 (3.4) 6.8 (3.3) .779 
Males, % 43.7 48.0 39.3 .130 48.0 42.2 .382 
SCD phenotype (HbSS/HbSβ0/HbSD), % 75.0 68.7 81.3 .011 NA NA NA 
Hemoglobin, mean (SD), g/dL 9.5 (1.8) 9.9 (1.8) 9.2 (1.8) .001 11.2 (1.6) 9.0 (1.5) <.001 
Reticulocyte, mean (SD), % (n = 265) 8.0 (5.6) 9.0 (6.5) 7.2 (4.6) .009 4.2 (3.0) 9.2 (5.7) <.001 
On hydroxyurea, % 58.7 60.0 57.3 .639 29.3 68.4 <.001 
Death, % 15.3 14.7 16.0 .749 16.0 15.1 .853 
Median age of survival for adults with SCD, by starting initial survival age (N = 300) 
 Median (95% CI): survival to ≥18 y 49.2 (44.4-58.4) (n = 300) 43.6 (40.6-59.5) (n = 150) 54.1 (46.3-62.9) (n = 150) .191 54.7 (38.6-62.9) 48.0 (44.4-58.4) .889 
 Median (95% CI): survival to ≥25 y 54.7 (46.3-60.6) (n = 198) 54.7 (43.3-60.6) (n = 80) 54.1 (46.3-62.9) (n = 118) .858 56.5 (38.6-62.9) (n = 53) 51.4 (44.9-59.5) (n = 145) .926 
 Median (95% CI): survival to ≥30 y 56.5 (46.3-60.6) (n = 138) 54.7 (40.6-undefined) (n = 42) 56.5 (46.4-62.9) (n = 96) .815 54.7 (38.6-62.9) (n = 38) 54.1 (46.1-66.1) (n = 100) .760 

IQR, interquartile range; NA, not applicable; SD, standard deviation.

*

χ2 test for categorical variables and Student t test for continuous variables, unless otherwise indicated.

Mann-Whitney U test.

Log-rank test for comparison of survival distribution.

Close Modal

or Create an Account

Close Modal
Close Modal